Loading...
•
Sep 30, 2020
Nkarta Q3 2020 Earnings Report
Nkarta reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Nkarta reported a net loss of $13.7 million, or $0.44 per share, for the third quarter of 2020. The company ended the quarter with $330.2 million in cash and cash equivalents.
First patient dosed in clinical trial of NKX101 in acute myeloid leukemia and myelodysplastic syndromes.
IND application for NKX019 expected to be filed in 1Q 2021.
Ended third quarter 2020 with $330.2 million of cash and cash equivalents.
Cash and cash equivalents are believed to be sufficient to fund operations into at least the second half of 2023.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023. The company expects cash and cash equivalents at December 31, 2020 to be in the range of $300 million to $310 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...